Amakem

DIEPENBEEK, Belgium, November 2, 2011 - Kinase inhibitor reduces inflammation in the lungs in COPD model with no cardiovascular side effects Amakem NV, a kinase platform company focusing on ophthalmology, today presented further data demonstrating the effectiveness of its 'Localized Drug Action' approach at the Discovery on Target conference in Boston, MA.